Results 1 to 10 of about 1,044,683 (223)

Peripheral neurotoxicity induced by albumin-bound paclitaxel: a case report [PDF]

Frontiers in Oncology
BackgroundDespite its excellent therapeutic efficacy, albumin-bound paclitaxel often leads to peripheral neurotoxicity, significantly affecting patients’ quality of life.
Xiaojing Li, Liuting Wu, Dunyao Bai, Juan Li   +3 more
doaj   +6 more sources

Efficacy of albumin-bound paclitaxel versus paclitaxel in esophageal cancer: a systematic review and meta-analysis [PDF]

Frontiers in Oncology
ObjectiveTo systematically evaluate the efficacy and safety of albumin-bound paclitaxel and paclitaxel in the treatment of esophageal cancer.MethodsSeven databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang Data ...
Jiayang Song, Yu Xiong, Yu Xiong, Hao Liu, Wei Zhang, Zhongfu Tan, Nanjiang Liu   +6 more
doaj   +6 more sources

Comparison of Peripheral Neuropathy Induced by Standard and Nanoparticle Albumin–Bound Paclitaxel in Rats

Journal of Pharmacological Sciences, 2011
.: Nanoparticle albumin–bound paclitaxel (nab-paclitaxel) is delivered to tumors and increases antitumor activity compared with solvent-based paclitaxel.
Yuji Yamashita, Nobuaki Egashira, Ken Masuguchi, Soichiro Ushio, Takehiro Kawashiri, Ryozo Oishi   +5 more
doaj   +4 more sources

A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case–control study [PDF]

Science Progress
Purpose At present, albumin-bound paclitaxel combined with platinum is the standard first-line treatment option for advanced esophageal cancer (EC). However, following a hospitalization surge, clinicians may prefer to use albumin-bound paclitaxel as a ...
Jing Ren, Ke Wang, Jian Zhao, Chang Xu, Changqing Liu, Yusheng Wang, Guangyu Wang   +6 more
doaj   +2 more sources

Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort trial [PDF]

Cancer Immunology, Immunotherapy
Background This single-center, open-label, exploratory trial aimed to investigate the efficacy and safety of envafolimab combined with lenvatinib and chemotherapy in previous treated advanced G/GEJ adenocarcinoma.
Zhao Xiaoying, Feng Wanjing, Geng Qirong, Huang Mingzhu, Zhang Zhe, Chen Jinsi, Sheng Xuedan, Zhu Xiaodong, Guo Weijian   +8 more
doaj   +2 more sources

Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment for patients with human epidermal growth factor receptor 2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial [PDF]

Frontiers in Immunology
BackgroundCurrent first-line treatment options for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma have limited efficacy.
Chen Wu, Shuai Li, Xinfang Hou
doaj   +2 more sources

Evaluate the Clinical Outcome of Nanoparticle Albumin-bound Paclitaxel on Breast Cancer Treatment: A Systematic Review and Meta-analysis [PDF]

International Journal of Scientific Research in Dental and Medical Sciences, 2022
Background and aim: Nanoparticle albumin-bound paclitaxel can have a higher response rate than paclitaxel in women with metastatic breast cancer. Therefore, the present study was conducted to evaluate the clinical outcome of nanoparticle albumin-bound ...
Yasaman Shariati, Fatemeh Salehi Kahrizsangi, Niloofarsadat Hozhabrossadati, Donya Naseri, Mandana Ebrahimi   +4 more
doaj   +1 more source

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy

BMC Pharmacology and Toxicology, 2023
Background Albumin-bound paclitaxel (nab-paclitaxel), as a special targeted preparation of paclitaxel, has the advantages of good curative effect and less side effects in anti-tumor therapy. The existence of the plasma-peritoneal barrier and insufficient
Jingjing Zhang, Luya Li, Jintuo Yin, Xidong Zhang, Ying Zheng, Rui Feng   +5 more
doaj   +1 more source

Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3 [PDF]

Zhongguo aizheng zazhi
Background and purpose: The resistance of pancreatic cancer to albumin-bound paclitaxel affects the therapeutic effect and prognosis. Signal transducer and activator of transcription 3 (STAT3) is one of the important molecules regulating the chemotherapy
FU Hua, ZHOU Guochao, CAI Rongmin, SONG Xin, YANG Dinghua
doaj   +3 more sources

Pure redox-sensitive paclitaxel–maleimide prodrug nanoparticles: Endogenous albumin-induced size switching and improved antitumor efficiency

Acta Pharmaceutica Sinica B, 2021
A commercial albumin-bound paclitaxel nano-formulation has been considered a gold standard against breast cancer. However, its application still restricted unfavorable pharmacokinetics and the immunogenicity of exogenous albumin carrier.
Xinyu Lou, Dong Zhang, Hao Ling, Zhonggui He, Jin Sun, Mengchi Sun, Dongchun Liu   +6 more
doaj   +1 more source